‘Morbius’ Reportedly Delayed for ‘Spider-Man: No Way Home’ Box Office Success
With the latest entry into the MCU’s Peter Parker saga becoming one of the most successful films of all time, Sony has apparently tried hard to preserve its run, as Morbius is reportedly delayed for Spider-Man: No Way Home box office success.
With Morbius getting delayed once again, the Jared Leto helmed vampire film has once again struggled to find an audience.
The film exploring the obscure comic book villain is a look at the sympathetic Michael Morbius, a character known as one of the more interesting members of Spider-Man’s illustrious Rogues gallery.
The reasoning for Morbius’s continued delay, however, seems to be up for debate. With reports now claiming that its push back has less to do with the rise in COVID-19 cases that everyone had assumed.
As first reported by ComicBook.com – writing from previous insight by way of Deadline – Morbius is reportedly delayed for Spider-Man: No Way Home box office success.
ComicBook.com writes, “Sony didn’t want to movies to step on each other’s toes, for lack of better word. Now that Morbius doesn’t hit theaters until sprint, that gives time for No Way Home to complete its record-setting run before another superhero feature hits theaters.”
The logic is not completely flawed, with the Sony wanting Spider-Man: No Way Home to complete its theatrical release window unimpeded by any other film that takes place in the genre while also preserving the audience for Morbius without having the film compete with 2021’s biggest movie.
It does seem a little odd, however, for this to be the reasoning considering the rise of COVID-19 cases due to the Omnicron variant, and the hesitancy for general audiences to brave theaters once again.
Spider-Man: No Way Home was a film built on the celebration of over 20 years of cinematic appearances, while also acting as a financial anomaly in the pandemic era box office.
Morbius will likely struggle to find an audience due to its obscure focus but will have Sony’s developing Spider-Verse of films to propel it to some semblance of success.
A continued delay was in the best interest of Morbius; not because Spider-Man: No Way Home could exceed its already $1 billion box office triumphs, but because COVID-19 cases limit the consumer base available to a film like Morbius.
Whether or not the reports are true, it is interesting to consider just how massive the orbit surrounding Spider-Man: No Way Home has become.